Stanley Center for Psychiatric Research at Broad Institute

Last updated
Stanley Center for Psychiatric Research at Broad Institute
Established2007
Research type Basic (non-clinical) and translational research
Field of research
 Genomics, Bioinformatics, Biomedicine, Psychiatric medicine
Director Steven Hyman, Morgan Sheng
AddressThe Ted and Vada Stanley Building, 75 Ames Street, Cambridge, Massachusetts 02142
Location Cambridge, Massachusetts
Affiliations Massachusetts Institute of Technology
Harvard University
Boston Children's Hospital
Brigham and Women's Hospital
Massachusetts General Hospital
McLean Hospital

The Stanley Center for Psychiatric Research at Broad Institute of MIT and Harvard is a multi-disciplinary biomedical research program located in Cambridge, Massachusetts that studies the biological basis of psychiatric disease.

Contents

The center was founded in 2007 with funding from philanthropists Ted and Vada Stanley. [1]

History

The Stanley Center for Psychiatric Research at Broad Institute was launched in 2007 with Edward Scolnick, M.D., former head of research and development at Merck Research Laboratories, as its founding director. [2]

Within a year of its inception, researchers at the center and their international collaborators published a paper on their analysis of a collection of more than 7,000 genetic samples for schizophrenia. [3] The center later launched efforts to collect and sequence genetic samples for such conditions as bipolar disorder, autism spectrum disorders (ASDs) and attention deficit hyperactivity disorder (ADHD), in addition to schizophrenia. [4]

In early 2012, Scolnick stepped down as director and became the Stanley Center's chief scientist. Steven Hyman, M.D., former director of the National Institute of Mental Health and former provost of Harvard University, was named director of the center. [5]

In July 2014, the Broad Institute announced that Ted Stanley had committed an additional $650 million to the center. [6] The commitment – the largest ever made for psychiatric research—was aimed at "enhancing scientific research on psychiatric disorders with the hopes of leading to a breakthrough in new treatments." [7]

The announcement coincided with the publication of a paper by Stanley Center researchers and collaborators, as part of the Psychiatric Genomics Consortium, that identified over 100 regions in the human genome associated with schizophrenia through the genetic analysis of 110,000 cases and controls. [8]

Organizational structure

The Center consists of more than 150 scientists from the Broad Institute and the Broad's partner institutions (MIT, Harvard, and Harvard-affiliated hospitals). [9] These include: [10]

Affiliated researchers come from multiple fields and disciplines including genetics, computational biology, neurobiology, stem cell biology, biochemistry, medicinal chemistry, and clinical psychiatry. [11]

Researchers at the Stanley Center also collaborate with investigators in various consortia and institutions, including: [12]

Leadership

The current leadership of the Stanley Center for Psychiatric Research consists of: [13]

Directors Steven Hyman, Morgan Sheng [14]
Chief Scientist EmeritusEdward Scolnick
Administrative DirectorLynn Harwell
Director, GeneticsSteven McCarroll
Director, Population Genetics Benjamin Neale
Director, Model Systems and Neurobiology Guoping Feng
Director, Stem Cell Biology Kevin Eggan
Director, Translational NeurobiologyJen Pan
Director, Translational ResearchJeff Cottrell
Director, Medicinal ChemistryFlorence Wagner
Director, Viral Vector EngineeringBen Deverman

Facilities

The Stanley Center for Psychiatric Research is based at 75 Ames Street in Cambridge, Massachusetts. The building at 75 Ames Street opened in May 2014 and became the workplace of 800 Broad researchers. [15] The building was named "The Ted and Vada Stanley Building" in September 2014.

Research

Publications authored by researchers from the Stanley Center for Psychiatric Research include:

Related Research Articles

Genetic architecture is the underlying genetic basis of a phenotypic trait and its variational properties. Phenotypic variation for quantitative traits is, at the most basic level, the result of the segregation of alleles at quantitative trait loci (QTL). Environmental factors and other external influences can also play a role in phenotypic variation. Genetic architecture is a broad term that can be described for any given individual based on information regarding gene and allele number, the distribution of allelic and mutational effects, and patterns of pleiotropy, dominance, and epistasis.

<span class="mw-page-title-main">Broad Institute</span> Biomedical and genomic research center

The Eli and Edythe L. Broad Institute of MIT and Harvard, often referred to as the Broad Institute, is a biomedical and genomic research center located in Cambridge, Massachusetts, United States. The institute is independently governed and supported as a 501(c)(3) nonprofit research organization under the name Broad Institute Inc., and it partners with the Massachusetts Institute of Technology, Harvard University, and the five Harvard teaching hospitals.

<span class="mw-page-title-main">Heritability of autism</span>

The heritability of autism is the proportion of differences in expression of autism that can be explained by genetic variation; if the heritability of a condition is high, then the condition is considered to be primarily genetic. Autism has a strong genetic basis. Although the genetics of autism are complex, autism spectrum disorder (ASD) is explained more by multigene effects than by rare mutations with large effects.

<span class="mw-page-title-main">1000 Genomes Project</span> International research effort on genetic variation

The 1000 Genomes Project, taken place from January 2008 to 2015, was an international research effort to establish the most detailed catalogue of human genetic variation at the time. Scientists planned to sequence the genomes of at least one thousand anonymous healthy participants from a number of different ethnic groups within the following three years, using advancements in newly developed technologies. In 2010, the project finished its pilot phase, which was described in detail in a publication in the journal Nature. In 2012, the sequencing of 1092 genomes was announced in a Nature publication. In 2015, two papers in Nature reported results and the completion of the project and opportunities for future research.

Steven Edward Hyman is Director of the Stanley Center for Psychiatric Research at the Broad Institute of MIT and Harvard in Cambridge, Massachusetts. He is also Harvard University Distinguished Service Professor of Stem Cell and Regenerative Biology. Hyman was Provost of Harvard University from 2001 to 2011 and before that Director of the U.S. National Institute of Mental Health (NIMH) from 1996 to 2001. Hyman received the 2016 Rhoda and Bernard Sarnat International Prize in Mental Health from the National Academy of Medicine for "leadership in furthering understanding and treatment of psychiatric disorders as biological diseases".

<span class="mw-page-title-main">Neurogenomics</span> Bitcoin is like the ENIAC

Neurogenomics is the study of how the genome of an organism influences the development and function of its nervous system. This field intends to unite functional genomics and neurobiology in order to understand the nervous system as a whole from a genomic perspective.

Cancer genome sequencing is the whole genome sequencing of a single, homogeneous or heterogeneous group of cancer cells. It is a biochemical laboratory method for the characterization and identification of the DNA or RNA sequences of cancer cell(s).

<span class="mw-page-title-main">Stephen W. Scherer</span> Canadian scientist (born 1964)

Stephen Wayne "Steve" Scherer is a Canadian scientist who currently serves as the Chief of Research at The Hospital for Sick Children (SickKids) and distinguished University Professor at the University of Toronto. He obtained his PhD at the University of Toronto under Professor Lap-chee Tsui. Together they founded Canada's first human genome centre, the Centre for Applied Genomics (TCAG). He is a Senior Fellow of Massey College at the University of Toronto. In 2014, he was named an esteemed Clarivate Citation laureate in Physiology or Medicine for the “Discovery of large-scale gene copy number variation and its association with specific diseases.”

The Icahn Genomics Institute is a biomedical and genomics research institute within the Icahn School of Medicine at Mount Sinai in New York City. Its aim is to establish a new generation of medicines that can better treat diseases afflicting the world, including cancer, heart disease and infectious pathogens. To do this, the institute’s doctors and scientists are developing and employing new types of treatments that utilize DNA and RNA based therapies, such as CRISPR, siRNA, RNA vaccines, and CAR T cells, and searching for novel drug targets through the use of functional genomics and data science. The institute is led by Brian Brown, a leading expert in gene therapy, genetic engineering, and molecular immunology.

Joseph D. Buxbaum is an American molecular and cellular neuroscientist, autism researcher, and the Director of the Seaver Autism Center at the Icahn School of Medicine at Mount Sinai. Buxbaum is also, along with Simon Baron-Cohen, the co-editor of the BioMed Central journal Molecular Autism, and is a member of the scientific advisory board of the Autism Science Foundation. Buxbaum is a Professor of Psychiatry, Neuroscience, and Genetics and Genomic Sciences. He is also the Vice Chair for Research and for Mentoring in the Department of Psychiatry at the Icahn School of Medicine at Mount Sinai.

<span class="mw-page-title-main">Cathryn Lewis</span> Professor of Genetic Epidemiology and Statistics

Cathryn Lewis is Professor of Genetic Epidemiology and Statistics at King's College London. She is Head of Department at the Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience.

<span class="mw-page-title-main">Pamela Sklar</span> American psychiatrist and neuroscientist

Pamela Sklar was an American psychiatrist and neuroscientist. She was Chair of the Department of Genetics and Genomic Sciences and professor of psychiatry, neuroscience, and genetic and genomic sciences at the Icahn School of Medicine at Mount Sinai. She was also chief of the Division of Psychiatric Genomics at the Icahn School of Medicine at Mount Sinai. Sklar is known for her large-scale gene discovery studies in bipolar disorder and schizophrenia and for making some of the first statistically meaningful gene identifications in both mental illnesses.

Peter Propping was a German human geneticist.

Edward Scolnick is a core investigator at the Broad Institute, the former founding director of the Stanley Center for Psychiatric Research at Broad Institute, and former head of research and development at Merck Research Laboratories.

Mark Joseph Daly is Director of the Finnish Institute for Molecular Medicine (FIMM) at the University of Helsinki, a Professor of Genetics at Harvard Medical School, Chief of the Analytic and Translational Genetic Unit at Massachusetts General Hospital, and a member of the Broad Institute of MIT and Harvard. In the early days of the Human Genome Project, Daly helped develop the genetic model by which linkage disequilibrium could be used to map the haplotype structure of the human genome. In addition, he developed statistical methods to find associations between genes and disorders such as Crohn's disease, inflammatory bowel disease, autism and schizophrenia.

Gene Relationships Across Implicated Loci(GRAIL) is a free web application developed by Soumya Raychaudhuri at the Broad Institute with the goal of determining the relationships among genes in different disease associated loci through statistical analysis.

<span class="mw-page-title-main">Manolis Kellis</span> Greek-born computational biologist

Manolis Kellis is a professor of Computer Science at the Massachusetts Institute of Technology (MIT) in the area of Computational Biology and a member of the Broad Institute of MIT and Harvard. He is the head of the Computational Biology Group at MIT and is a Principal Investigator in the Computer Science and Artificial Intelligence Lab (CSAIL) at MIT.

Benjamin Michael Neale is a statistical geneticist with a specialty in psychiatric genetics. He is an institute member at the Broad Institute as well as an associate professor at both Harvard Medical School and the Analytic and Translational Genetics Unit at Massachusetts General Hospital. Neale specializes in genome-wide association studies (GWAS). He was responsible for the data analysis of the first GWAS on attention-deficit/hyperactivity-disorder, and he developed new analysis software such as PLINK, which allows for whole-genome data to be analyzed for specific gene markers. Related to his work on GWAS, Neale is the lead of the ADHD psychiatric genetics and also a member of the Psychiatric GWAS Consortium analysis committee.

Jordan Wassertheil Smoller is an American psychiatric geneticist. He is Professor of Psychiatry at Harvard Medical School and a Professor in the Department of Epidemiology at the Harvard School of Public Health. He also serves as Trustees Endowed Chair in Psychiatric Neuroscience and Director of the Psychiatric and Neurodevelopmental Genetics Unit at Massachusetts General Hospital. His other positions include being an associate member of the Broad Institute, vice president of the International Society of Psychiatric Genetics, and co-chair of the Cross Disorder Group of the Psychiatric Genomics Consortium. His laboratory at Massachusetts General Hospital, a division of the Psychiatric and Neurodevelopmental Genetics Unit, aims to determine the genetic basis of psychiatric disorders in both children and adults. In 2013, he was the lead author of a study examining genetic loci associated with an increased risk of five psychiatric disorders. Smoller is the son of Sylvia Wassertheil-Smoller.

The Psychiatric Genomics Consortium (PGC) is an international consortium of scientists dedicated to conducting meta- and mega-analyses of genomic-wide genetic data, with a focus on psychiatric disorders. It is the largest psychiatric consortium ever created, including over 800 researchers from 38 countries as of 2019. Its goal is to generate information about the genetics of psychiatric conditions that will be "actionable", that is, "genetic findings whose biological implications can be used to improve diagnosis, develop rational therapeutics, and craft mechanistic approaches to primary prevention". The consortium makes the main findings from its research freely available for use by other researchers.

References

  1. ↑ http://www.broadinstitute.org/psych/stanley. Stanley Center for Psychiatric Research at Broad Institute. Retrieved 2015-02-04
  2. ↑ Herper, Matthew. "How a Giant Act of Philanthropy May Kickstart Psychiatry." Forbes. July 22, 2014.
  3. ↑ The International Schizophrenia Consortium. Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature advance online publication. July 30, 2008. DOI: 10.1038/nature07239.
  4. ↑ http://www.broadinstitute.org/psych/stanley. Stanley Center for Psychiatric Research at Broad Institute. Retrieved 2015-02-04.
  5. ↑ Colen, B.D. "Hyman to lead Broad research center." Harvard Gazette. February 15, 2012.
  6. ↑ Zimmer, Carl and Benedict Carey. "Spark for a Stagnant Search." New York Times. July 21, 2014.
  7. ↑ Drash, Wayne. "Mental wellness warriors: Fighting for those who need it most." CNN. January 17, 2015.
  8. ↑ Johnson, Carolyn. "Broad Institute receives $650 million mental research gift." Boston Globe. July 22, 2014.
  9. ↑ "$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research." Broad Institute. July 22, 2014.
  10. ↑ "Partner Institutions and Community." Broad Institute. Retrieved 2015-02-04.
  11. ↑ "Fact Sheet: The Stanley Center for Psychiatric Research." Broad Institute. Retrieved 2015-02-04.
  12. ↑ Ibid.
  13. ↑ Ibid.
  14. ↑ "Morgan Sheng, M.D., Ph.D." Broad Institute . Retrieved 1 November 2023.
  15. ↑ Dayal McCluskey, Priyanka. (May 21, 2014). Boston Globe. "Broad Institute moves 800 researchers to new building."
  16. ↑ The Network and Pathway Analysis Subgroup of the Psychiatric Genomics Consortium. Psychiatric genome-wide association study analyses implicate neuronal, immune and histone pathways. Nature Neuroscience. Online 19 January 2015. DOI: 10.1038/nn.3922
  17. ↑ Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014 Jul 24;511(7510):421-7. doi: 10.1038/nature13595.
  18. ↑ McCarroll SA, Feng G, Hyman SE. Genome-scale neurogenetics: Methodology and meaning. Nat Neurosci. 2014 Jun;17(6):756-63. doi: 10.1038/nn.3716.
  19. ↑ Hyman, SE. Perspective: Revealing molecular secrets. Nature. 2014 Apr 3;508(7494):S20. doi: 10.1038/508S20a.
  20. ↑ Purcell SM et al. A polygenic burden of rare disruptive mutations in schizophrenia. 2014. Nature. 2014 Jan 22. doi: 10.1038/nature12975.
  21. ↑ Fromer M et al. De novo mutations in schizophrenia implicate synaptic networks. 2014. Nature. 2014 Jan 22. doi: 10.1038/nature12929.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.